Thermo Fisher Scientific, Inc. has launched new BRAHMS PCT testing solution for the Samsung IB10 point-of-care platform. For healthcare professionals facing the complexity of daily requirements in emergency situations, a new point-of-care test, Samsung IB Thermo Fisher launches new testing solution for Samsung IB10 platform PCT assay, offers an integrated solution for accurate sepsis diagnosis and antibiotic stewardship. The test, which recently received a CE mark for use in Europe, may further improve medical decision-making about risk assessment and therapy management.

Thermo Fisher launches new testing solution for Samsung IB10 platform PCT (procalcitonin) assays are known to clinicians for high-quality and reliable early detection of bacterial infections based on standardized cutoffs. The quantitative point of care test aids early detection and diagnosis of clinically relevant bacterial infections to assess the degree of severity and to prognosticate the outcome of systemic bacterial infection, sepsis, severe sepsis, and septic shock. The Samsung IB BRAHMS PCT test is not available for sale in some countries, including the US.